

Alpha feto-protien as a Biochemical Marker in prediction of morbidly adherent placenta

Thesis

Submitted as Partial Fulfillment of Master Degree
in Obstetrics and Gynecology

By

Kyrollos Refat Khalf Marzok

M.B.B.Ch – Ain Shams University – 2013

Under Supervision of

Prof. Dr. Hassan Tawfik Khairy

Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University

Dr. Mohammed Saeed Eldin El Safty

Assistant Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University

Dr. Rasha Medhat Abd El Hadi

Lecturer of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University

**Faculty of Medicine
Ain Shams University
2019**



Acknowledgments

*First and foremost, I feel always indebted to **Allah**, the Most Merciful, Who gives me power to accomplish this work,*

*I would like to express my deepest appreciation and sincere gratitude to **Prof. Dr. Hassan Tawfik Khairy**, Professor of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University, for his sincere help, constant encouragement, constructive criticism, and valuable guidance; I was truly honored to work under his supervision.*

*Special thanks go to **Dr. Mohammed Saeed Eldin El Safty** Assistant Professor of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University, for his guidance, continuous support and encouragement through the whole work,*

*Special thanks go to **Dr. Rasha Medhat Abd El Hadi**, Lecturer of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University, for her great efforts and time she has devoted to accomplish this work,*

*I owe special thanks to **Family**, especially my Parents for pushing me forward in every step in the journey of my life.*

Special thanks to my wife dr. Haidy Malak Hana for her contribution in collecting & revising data.

 **Kyrollos Refat Khalf Marzok**



Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	iii
List of Figures	v
Introduction	1
Aim of the Work	4
Review of Literature	
 Placenta Accreta.....	5
 Management of Placenta Accreta	18
 Role of Imaging in Placenta Accreta	33
 Alpha-Fetoprotein	46
Patients and Methods	59
Results	79
Discussion	105
Summary	118
Conclusions and Recommendations	124
References	125
Arabic Summary	

List of Abbreviations

<i>Abbr.</i>	<i>Full term</i>
2DUS	: Two-dimensional ultrasound
3D	: Three-dimensional
3DPD	: 3 dimensional power doppler
3DUS	: Three-dimensional ultrasound
ACOG	: American College of Obstetricians and Gynecologist
AJOG	: American Journal of Obstetrics and Gynecology
AUC	: Area under the curve
AFP	: Alpha feto-protien
CS	: Cesarean section
EGFR	: Epidermal growth factor receptor
FFP	: Fresh frozen plasma
IIA	: Internal iliac artery
MAP	: Morbidly adherent placenta
MNGCs	: Number of multinucleated giant cells magnetic
MRI	: Magnetic resonance imaging
MS US	: Multislice ultrasound
MSV	: Multi-Slice View
NPV	: Negative predictive value
OMD	: Orthogonal display mode
PAD	: Placental adhesion disorders
PPV	: Positive predictive value
PRBCs	: Packed red blood cells.

List of Abbreviations *(Cont.)*

<i>Abbr.</i>	<i>Full term</i>
RCOG	: Royal College of Obstetricians and Gynecologist
ROC	: Receiver operating characteristic (ROC)
ROI	: Region of interest
SD	: Standard deviation
SPSS	: Statistical package for social sciences
UA	: Uterine artery
US	: Ultrasound
VEGFR-2	: Vascular endothelial growth factor receptor-2

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Characteristics of the whole study population.....	80
Table (2):	Characteristics of patients with Non-adherent placenta and those with Adherent placenta	81
Table (3):	Results of 2D grayscale US with 3DPD and 3D power Doppler with MS US examination in patients with non-adherent placenta and those with adherent placenta.	84
Table (4):	Results of serum AFP assay in patients with non-adherent placenta and those with adherent placenta.	85
Table (5):	Operative details in patients with non-adherent placenta and those with adherent placenta.	87
Table (6):	Diagnostic value of 2D grayscale US with 3DPD for identification of adherent placenta.	90
Table (7):	Diagnostic value of 3D power Doppler with MS US for identification of adherent placenta.	92
Table (8):	Diagnostic value of elevated AFP (>2.5 MoM) for identification of adherent placenta.	94
Table (9):	Receiver-operating characteristic (ROC) curve analysis for the value of quantitative AFP assay in the diagnosis of adherent placenta.	96

List of Tables *(Cont.)*

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (10):	Diagnostic value of a AFP cut-off level of (0.9375 MoM) for identification of adherent placenta.3	98
Table (11):	Comparison of the sensitivities* of AFP >0.9375 MoM, 2D grayscale US, 3DPD and 3D power Doppler with MS US	100
Table (12):	Comparison of the specificities* of AFP >0.9375 MoM, 2D grayscale US, 3DPD and 3D power Doppler with MS US	101
Table (13):	Multivariable binary logistic regression analysis for the diagnostic value of 2D grayscale US with 3DPD combined with quantitative AFP assay.	102
Table (14):	Comparison of the ROC curves associated with quantitative AFP assay, 2DUSwith 3DPD, or Quantitative AFP assay and 2DUS with 3DPD combined.	103

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Photomicrograph of the utero-placental interface of a placenta accreta at term.....	13
Figure (2):	Early pregnancy	16
Figure (3):	Pregnancy complicated with placenta percreta	17
Figure (4):	Perioperative view of a placenta percreta left in situ after the closing of the vertical fundal uterine incision.....	22
Figure (5):	Placenta percreta with bladder invasion at cesarean delivery Lower uterine segment is bulbous with areas of hemorrhage beneath visceral peritoneum and prominent distended vessels.....	32
Figure (6):	Gray-scale and color Doppler images showing sonographic diagnostic criteria for morbidly adherent placenta.....	35
Figure (7):	Three-dimensional power Doppler used to map intraplacental vascularization and vascularization of uterine serosa–bladder interface.....	37
Figure (8):	MRI: Abnormal uterine bulging	39
Figure (9):	MRI: heterogeneity of signal intensity within the placenta.....	40
Figure (10):	MRI: presence of dark intraplacental bands on T2-weighted images	40
Figure (11):	General electric Voluson E6	63
Figure (12):	2D grayscale showing focal exophytic mass in case of percreta	65

List of Figures *(Cont.)*

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (13):	2 D gray scale showing multiple abnormal placental lacunae with loss and disruption of the retroplacenta l sonolucent zone.....	65
Figure (14):	Placental invasion.....	68
Figure (15):	Normal placentation.....	70
Figure (16):	3D multislice showing normal placentation ..	71
Figure (17):	Abnormal placentation	72
Figure (18):	Flow chart of patients through the study.....	79
Figure (19):	Box plot chart showing mean age of patients with non-adherent placenta and those with adherent placenta.....	82
Figure (20):	Bar chart showing parity in patients with non-adherent placenta and those with adherent placenta.	82
Figure (21):	Bar chart showing number of previous cesarean deliveries in patients with non-adherent placenta and those with adherent placenta.	83
Figure (22):	Bar chart showing percentage of patients with evidence of placental invasion by 2D grayscale US or 3D power Doppler with MS US examination and those with elevated (>2.5 MoM) AFP level among patients with non-adherent placenta and those with adherent placenta.....	85
Figure (23):	Box plot showing AFP level in patients with non-adherent placenta and those with adherent placenta.	86

List of Figures *(Cont.)*

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (24):	Box plot chart showing mean gestational age at delivery in patients with non-adherent placenta and those with adherent placenta.	88
Figure (25):	Rate of performance of additional surgical procedures in patients with normal placenta and those with abnormal placentation.	89
Figure (26):	Incidence of unwanted intraoperative outcomes in patients with non-adherent placenta and those with adherent placenta.	89
Figure (27):	Performance of 2D grayscale US with 3DPD for identification of adherent placenta.	91
Figure (28):	Performance of 3D power Doppler with MS US for identification of adherent placenta.	93
Figure (29):	Performance of elevated AFP (>2.5 MoM) for identification of adherent placenta.	95
Figure (30):	Receiver-operating characteristic (ROC) curve for the value of quantitative AFP assay in the diagnosis of adherent placenta.	97
Figure (31):	Performance of AFP cut-off level of >0.9375 MoM for identification of adherent placenta.	99

Alpha feto-protien as a Biochemical Marker in prediction of morbidly adherent placenta

Protocol of Thesis

Submitted as Partial Fulfillment of Master Degree
in Obstetrics and Gynecology

By

Kyrollos refaat khalaf marzok

M.B.B.Ch – Ain Shams University – 2013

Under Supervision of

Prof. Dr. Hassan Tawfik Khairy

Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University

Dr. Mohammed Saeed Eldin El Safty

Assistant Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University

Dr. Rasha Medhat Abd El Hadi

Lecturer of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University

**Faculty of Medicine
Ain Shams University
2018**

Introduction

Placenta accrete is a potentially life-threatening condition that requires a multidisciplinary approach to management. The incidence of placenta accrete has increased and seem to parallel the increasing cesarean delivery rate. Women at greatest risk of placenta accrete are those who have myometrial damage caused by previous cesarean delivery with either an anterior or posterior placenta previa overlying the uterine scar. Diagnosis of placenta accrete before delivery allows multidisciplinary planning in an attempt to minimize potential maternal or neo natal morbidity and mortality.(ACOG,2012)

In general, the recommended management of suspected placenta accreta is planned preterm cesarean hysterectomy with the placenta left in situ because attempts at removal of the placenta are associated with significant hemorrhagic morbidity. Although a planned delivery is the goal, a contingency plan for an emergency delivery should be developed for each patient, which may include following an institutional protocol for maternal hemorrhage management (ACOG, 2012).

Researchers have reported the incidence of placenta accreta as 1 in 533 pregnancies for the period of 1982–2002 (Wu et al., 2005). This contrasts sharply with previous reports, which ranged from 1 in 4,027 pregnancies in the 1970s, increasing to 1 in 2,510 pregnancies in the 1980s (Miller et al., 1997).

Abnormal placentation poses a diagnostic and treatment challenge for all providers caring for pregnant women. As one of the leading causes of postpartum hemorrhage, abnormal placentation involves the attachment of placental villi directly to the myometrium with potentially deeper invasion into the uterine wall or surrounding organs. Surgical procedures that disrupt the integrity of uterus, including cesarean section, dilatation and curettage, and myomectomy, have been implicated as key risk factors for placenta accrete (Megier et al., 2000).

Prenatal diagnoses of placenta accreta through the use of gray-scale ultrasonography, color Doppler imaging, and magnetic resonance imaging have been reported previously (**Chou et al., 1997**).

Placenta increta and percreta have rarely been diagnosed antepartum, and ultrasonographic findings may provide the only objective evidence of placenta accreta. A biochemical marker for this condition would therefore be useful (**Ophir et al., 1999**).

Alpha-fetoprotein (AFP) is found in both fetal serum and also amniotic fluid. This protein is produced early in gestation by the fetal yolk sac and then later in the liver and gastrointestinal tract. The true function of AFP is unknown (**Johnson et al., 2012**).

It is considered to be one of the most important markers which are used nowadays in early screening and diagnosis of many of high risk conditions and fetal abnormalities and malformations during pregnancy (**Dehghani-Firouzbad et al., 2010**).

For example maternal serum level of the Alpha-Fetoprotein is found by evidence to be raised hugely if the fetus has nervous system malformations as neural tube defects (example Spina bifida and anencephaly) or Down syndrome (**Wang et al., 2009**).

It is critical to make the diagnosis before delivery because preoperative planning can significantly decrease blood loss and avoid substantial morbidity associated with placenta accrete (**Shih et al., 2009**).

Aggressive management of hemorrhage through the use of uterotonics, fluid resuscitation, blood products, planned hysterectomy, and surgical hemostatic agents can be life-saving for these patients. Conservative management, including the use of uterine and placental preservation and subsequent methotrexate therapy or pelvic artery embolization, may be considered when a

focal accreta is suspected; however, surgical management remains the current standard of care **(Tseng et al., 2006)**.

Clinically, the most significant feature of placenta accreta is the abundant uteroplacental neovascularization, which can lead to life-threatening hemorrhage **(Finberg and Williams, 1992, Levine et al., 1997)**.

However, its antenatal diagnosis is usually based on characteristic findings on gray-scale ultrasound imaging, such as the loss of subendometrial echolucent zone or the presence of abnormal placental lacunae **(Comstock et al., 2004)**.

Despite the modern advances in imaging techniques, no single diagnostic technique affords complete assurance for the presence or absence of placenta accrete **(ACOG, 2006)**.

The diagnosis is most often made during the third stage of labor or on Cesarean delivery.

Aim& Objectives (Maximum 300 words)

The aim of this study is to compare between alpha-fetoprotein as biochemical marker & ultrasound & Doppler findings for prenatal predication of morbid adherent placentation in anterior placenta on scar of previous cesarean section.

Research Hypothesis

In pregnant women with previous cesarean delivery, placenta previa, and ultrasonographic findings of an abnormally adherent placenta; maternal serum alpha-fetoprotein may predict the presence of morbid adherent placenta accurately.

Research Question

Dose maternal serum alpha-fetoprotein level predict accurately the presence of morbid adherent placenta in pregnant women with previous cesarean delivery, placenta previa and ultrasonographic findings of an abnormally adherent placenta?